Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma
Clinical trial NCT05788107 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT05788107
- Sponsor
- Shanghai Henlius Biotech
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-01
- Primary completion
- 2025-05-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.